Answers are grounded in this paper and cite their sources.
Two molecular phenotypes have been identified in acute respiratory distress syndrome (ARDS). In the ROSE (Reevaluation of Systemic Early Neuromuscular Blockade) trial of cisatracurium in moderate to severe ARDS, we addressed three unanswered questions:
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: